These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18704213)

  • 21. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients.
    Aucoin MW; Wassersug RJ
    Soc Sci Med; 2006 Dec; 63(12):3162-73. PubMed ID: 16989928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
    Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
    Moyad MA
    Urol Oncol; 2005; 23(1):56-64. PubMed ID: 15885584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormonal therapy of prostate cancer: are there any dilemmas left?].
    Brucić LJ; Juretić A; Solarić M; Bisof V; Basić-Koretić M; Rakusić Z; Santek F
    Lijec Vjesn; 2012; 134(3-4):94-104. PubMed ID: 22768684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 32. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
    Bylow K; Mohile SG; Stadler WM; Dale W
    Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Patil T; Bernard B
    Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 37. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bisphosphonates in preventing skeletal complications of hormonal therapy.
    Gilbert SM; McKiernan JM
    Urol Clin North Am; 2006 May; 33(2):191-9, vi. PubMed ID: 16631457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
    Curtis KK; Pruthi RK; Fonseca R; Gornet MK
    Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.